Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support ...

An experimental antibiotic called EVG7 has shown promise against gram-positive bacterium Clostridioides difficile, the leading cause of healthcare and antibiotic-associated diarrhea in the US and ...

As the effectiveness of antibiotics meant to fight the deadly superbug Clostridioides difficile, or C. diff, wanes, a research team at the University of Houston is seeing positive results of a new ...

In a major step toward a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for Sick Children (SickKids) have uncovered how the body's bile acids bind to ...

In a major step towards a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for Sick Children (SickKids) have uncovered how the body's bile acids bind to ...

Clostridium difficile, commonly known as C difficile or C-diff, is rapidly gaining ground as the second-most destructive source of hospital-acquired infection after methicillin-resistant ...

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known as C. diff—are a serious and persistent problem for patients and hospitals ...

C. diff, short for Clostridioides difficile (formerly called Clostridum difficile), is a type of bacteria that can cause an infection in your colon, the longest part of your large intestine. In most ...